ESPR · Esperion Therapeutics, Inc.
Market Cap
$818.63M
Shares
257.43M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$403.14M
+21.3%
FY2025
Net Income
-$22.68M
+56.2%
FY2025
Operating Margin
14.95%
-1.4pp
FY2025
Diluted EPS
-$0.11
+60.7%
FY2025
Operating Cash Flow
-$13.09M
+44.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $418.24M | $403.14M | $332.31M | $116.33M | $75.48M | $78.45M | $227.55M | $148.36M | $0 | — | — | — | — | — | — | — | |
| $44.28M | $47.85M | $46.24M | $86.11M | $118.93M | $105.98M | $146.94M | $175.61M | $171.49M | $147.6M | $57.87M | $29.8M | $25.3M | $16.01M | $8M | $7.81M | |
| — | — | — | — | — | — | — | $65.85M | $33.1M | $21.38M | $18.28M | $20.24M | $10.92M | $6.75M | $2.21M | $2.36M | |
| $165.91M | $165.79M | $163.07M | $142.52M | $109.08M | $184.99M | $199.62M | $65.85M | $33.1M | — | — | — | — | — | — | — | |
| $342.46M | $342.86M | $277.91M | $271.9M | $254.98M | $305.18M | $348.94M | $241.47M | $204.59M | $168.98M | $76.15M | $50.04M | $36.22M | $22.76M | $10.2M | $10.16M | |
| $75.79M | $60.27M | $54.4M | -$155.56M | -$179.5M | -$226.73M | -$121.4M | -$93.1M | -$204.59M | -$168.98M | -$76.15M | -$50.04M | -$36.22M | -$22.76M | -$10.2M | -$10.16M | |
| — | 14.95% | 16.37% | -133.72% | -237.83% | -289.02% | -53.35% | -62.75% | — | — | — | — | — | — | — | — | |
| $84.97M | $84.6M | $59.25M | $58.98M | $56.81M | $46.35M | $22.67M | $8.12M | $28K | $198K | $376K | $520K | $270K | $936K | $1.49M | $577.16K | |
| $3.6M | $3.49M | $8.02M | $5.29M | $2.65M | $3.98M | $515K | $4.06M | $2.8M | $2.19M | $1.17M | $776K | $119K | $194K | -$84K | -$75.81K | |
| — | -$20.84M | -$51.75M | -$209.25M | — | — | — | — | — | — | — | — | — | — | — | — | |
| $1.84M | $1.84M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$7.42M | -$22.68M | -$51.75M | -$209.25M | -$233.66M | -$269.11M | -$143.55M | -$97.17M | -$201.81M | -$166.99M | -$74.98M | -$49.78M | -$36.38M | -$26.09M | -$11.74M | -$10.82M | |
| — | -5.63% | -15.57% | -179.87% | -309.58% | -343.04% | -63.09% | -65.49% | — | — | — | — | — | — | — | — | |
| -$7.42M | -$22.68M | -$51.75M | -$209.25M | -$233.63M | -$269.14M | -$143.57M | -$96.82M | -$201.28M | -$167.66M | -$74.67M | -$50.21M | -$36.43M | -$26.09M | -$11.74M | -$10.82M | |
| USD/shares | — | -$0.11 | -$0.28 | -$2.03 | -$3.52 | -$9.31 | -$5.23 | -$3.59 | — | — | — | — | — | — | — | — |
| USD/shares | — | -$0.11 | -$0.28 | -$2.03 | -$3.52 | -$9.31 | -$5.23 | -$3.59 | — | — | — | — | — | — | — | — |
| shares | — | 207.87M | 187.18M | 103.11M | 66.41M | 28.9M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 7.89M | 323.38K | 298.69K |
| shares | — | 207.87M | 187.18M | 103.11M | 66.41M | 28.9M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 7.89M | 323.38K | 298.69K |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2025: $275M in buybacks.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.98×
EV/EBIT
—
Peer median 15.03×
P/E (TTM)
—
Peer median 14.39×
Peer medians compare against the 50 similar-size Drug Manufacturers - Specialty & Generic companies (of 104 listed).
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Collaboration Revenue | $243,566,000 | $216,589,000 | $37,999,000 | $19,612,000 | $38,400,000 | $214,582,000 | $148,364,000 | $0 |
| Product | $159,569,000 | $115,725,000 | $78,335,000 | $55,863,000 | $40,047,000 | $12,965,000 | $0 | $0 |
| Royalty Revenue From DSE And Sale Of Bulk Tablets And Milestones Received | $148,800,000 | $205,000,000 | $37,200,000 | $18,200,000 | — | — | — | — |
| License for Intellectual Property Revenue | — | — | — | — | — | — | $144,400,000 | — |
| Ongoing Regulatory and Development Activities Revenue | — | — | — | — | — | $1,600,000 | $4,000,000 | — |
| Royalty Revenue From DSE and Sale of Bulk Tablets | — | — | $37,200,000 | $18,200,000 | $9,900,000 | — | — | — |
| Royalty Revenue From DSE | — | — | — | — | $9,900,000 | $2,800,000 | — | — |
Key facts
CIK
1434868
CUSIP
29664W105
13F (30d)
182 filings
179 filers
Visit website
Investor relations